Advertisement

Heart Failure

Chapter
  • 742 Downloads
Part of the Contemporary Cardiology book series (CONCARD)

Abstract

Heart failure (HF) is a syndrome identified by well-defined symptoms and hemodynamic findings caused by an abnormality of cardiac function that results in a relative decrease in cardiac output (CO) that triggers compensatory renal and neurohormonal changes (Fig. 5.1.)

Keywords

Heart Failure Mitral Regurgitation Diastolic Dysfunction Cardiac Resynchronization Therapy Constrictive Pericarditis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Bibliography

  1. 1.
    Abraham WT, Fisher WG, Smith AL, et al. Cardiac resynchronization in chronic heart failure. New Engl J Med 2002;346:1845–53.PubMedCrossRefGoogle Scholar
  2. 2.
    Abraham WT, Fisher WG, Smith AL, et al., MIRACLE Study Group. Multicenter InSync Randomized Clinical Evaluation. Cardiac resynchronization in chronic heart failure. N Engl J Med 2002;346:1845–1853.PubMedCrossRefGoogle Scholar
  3. 3.
    The Acute Infarction Ramipril (AIRE) Study Investigators. Effects of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993;342:821.Google Scholar
  4. 4.
    Adams KF, Gheorghiade M, Uretsky BF, et al. Clinical benefits of low serum digoxin concentrations in heart failure. J Am Coll Cardiol 2002;39:946–953.PubMedCrossRefGoogle Scholar
  5. 5.
    Angeja BG, Grossman W. Evaluation and Management of Diastolic Heart Failure. Circulation 2003;107:659.PubMedCrossRefGoogle Scholar
  6. 6.
    Auricchio A, Stellbrink C, Butter C, et al., Pacing Therapies in Congestive Heart Failure II Study Group; Guidant Heart Failure Research Group. Clinical efficacy of cardiac resynchronization therapy using left ventricular pacing in heart failure patients stratified by severity of ventricular conduction delay. J Am Coll Cardiol 2003;42:2109–2116.PubMedCrossRefGoogle Scholar
  7. 7.
    Bardy GH, Lee KL, Mark DB, et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 2005;352:225–237.PubMedCrossRefGoogle Scholar
  8. 8.
    Bauersachs J, Heck M, Fraccarollo D, et al. additions of spironolactone to angiotensin converting enzyme inhibition in heart failure improves endothelial vasomotor dysfunction. J Am Coll Cardiol 2002;39:351–358.PubMedCrossRefGoogle Scholar
  9. 9.
    Baughman KL. B-type natriuretic peptide—a window to the heart. N Engl J Med 2002;347:158–159.PubMedCrossRefGoogle Scholar
  10. 10.
    Beta-Blocker Evaluation of Survival Trial Investigators. A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. N Engl J Med 2001;344:1659–1667.CrossRefGoogle Scholar
  11. 11.
    Bradley DJ, Bradley EA, Baughman KL, et al. Cardiac resynchronization and death from progressive heart failure: a meta-analysis of randomized controlled trials. JAMA 2003;289:730–740.PubMedCrossRefGoogle Scholar
  12. 12.
    Bristow MR. Beta-adrenergic receptor blockade in chronic heart failure. Circulation 2000;101:558–569.PubMedGoogle Scholar
  13. 13.
    The CAPRICORN Investigators: CAPRICORN: effect of CARVEDILOL on outcome after myocardial infarction in patients with left ventricular dysfunction. The CAPRICORN randomized trial. Lancet 2001;357:1385–1390.CrossRefGoogle Scholar
  14. 14.
    CIBIS-II Investigators and committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 1999;353:9–13.CrossRefGoogle Scholar
  15. 15.
    COPERNICUS: Packer M, Coats JS, Fowler MB, et al. for the carvedilol prospective randomized cumulative survival study group: effect of carvedilol on survival in severe chronic heart failure. New Engl J Med 2001;344:1651–1658.PubMedCrossRefGoogle Scholar
  16. 16.
    Cohn JN, Johnson G, Ziesche S, et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 1991;325:303.PubMedCrossRefGoogle Scholar
  17. 17.
    Delyani JA. Mineralocorticoid receptor antagonists. The evolution of utility and pharmacology. Kidney 2000;57:1408.CrossRefGoogle Scholar
  18. 18.
    The Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 1997;336:525–533.CrossRefGoogle Scholar
  19. 19.
    Elkayam U. Tolerance to organic nitrates: evidence, mechanisms, clinical relevance, and strategies for prevention. Ann Intern Med 1991;14:667.Google Scholar
  20. 20.
    Fowler MB, Vera-Llonch M, Oster G, et al. Influence of carvedilol on hospitalizations in heart failure: incidence, resource utilization and costs. US Carvedilol Heart Failure Study Group. J Am Coll Cardiol 2001;37:1692–1699.PubMedCrossRefGoogle Scholar
  21. 21.
    Granger CB, McMurray J, Yusuf S, et al. for the CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and reduced left ventricular systolic function intolerant to angiotensin converting enzyme inhibitors; the CHARM-alternative trial. Lancet 2003;362;772–776.PubMedCrossRefGoogle Scholar
  22. 22.
    Gheorghiade M, Fergurson D. Digoxin. A neurohormonal modulator in heart failure. Circulation 1991;84:2181.PubMedGoogle Scholar
  23. 23.
    Gheorghiade M, Hall V, Lakier JB, et al. Comparative hemodynamic and neurohormonal effects of intravenous captopril and digoxin and their combinations in patients with severe heart failure. J Am Coll Cardiol 1989;13:134.PubMedCrossRefGoogle Scholar
  24. 24.
    Goldstein S, Fagerberg B, Hjalmarson A, et al. Metoprolol controlled release/extended release in patients with severe heart failure: analysis of the experience in the MERIT-HF study. J Am Coll Cardiol 2001;38:932–938.PubMedCrossRefGoogle Scholar
  25. 25.
    Grossman W. Defining diastolic dysfunction. Circulation 2000;101:2020–2021.PubMedGoogle Scholar
  26. 26.
    Hickey AR, Wenger TL, Carpenter VP, et al. Digoxin immune fab therapy in the management of digitalis intoxication: safety and efficacy results of an observational surveillance study. J Am Coll Cardiol 1991;17:590.PubMedGoogle Scholar
  27. 27.
    Hjalmarson A, Goldstein S, Fagerberg B, et al. Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). MERIT-HF Study Group. JAMA 2000;283:1295–1302.PubMedCrossRefGoogle Scholar
  28. 28.
    Hogg K, Swedberg K, McMurray J. Heart failure with preserved left ventricular systolic function: epidemiology, clinical characteristics, and prognosi. J Am Coll Cardiol 2004;43:317–327.PubMedCrossRefGoogle Scholar
  29. 29.
    Hunt SH, Baker DW, Chin MH et al. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary: a report of the American College of Cardiology/American Heart Association task force on practice guidelines. J Am Coll Cardiol 2001:38:2101.PubMedCrossRefGoogle Scholar
  30. 30.
    Jessup M, Brozena S. Heart failure N Engl J Med 2003;48:2007–2018.CrossRefGoogle Scholar
  31. 31.
    Kass DA. Predicting cardiac resynchronization response by QRS duration: the long and short of it. J Am Coll Cardiol 2003;42:2125–2127PubMedCrossRefGoogle Scholar
  32. 32.
    Kazanegra R, Herrmann HC, McCullough PA; Breathing Not Properly Multinational Study Investigators. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med 2002;347:161–167.PubMedCrossRefGoogle Scholar
  33. 33.
    Kerwin WF, Botvinick EH, O’Connell JW, et al. Ventricular contraction abnormalities in dilated cardiomyopathy: effect of biventricular pacing to correct interventricular dyssynchrony. J Am Coll Cardiol 2000;35:1221–1227.PubMedCrossRefGoogle Scholar
  34. 34.
    Khan M. Gabriel. Heart failure in Cardiac drug therapy, sixth edition, Philadelphia, WB Saunders 2003.Google Scholar
  35. 35.
    Khand AU, Rankin AC, Martin W, Taylor J, Gemmell I, Cleland JG. Carvedilol alone or in combination with digoxin for the management of atrial fibrillation in patients with heart failure? J Am Coll Cardiol 2003;42:1944–1951.PubMedCrossRefGoogle Scholar
  36. 36.
    Lubien E, DeMaria A, Krishnaswamy P, et al. Utility of B-natriuretic peptide in detecting diastolic dysfunction: comparison with Doppler velocity recordings. Circulation 2002;105:595–601.PubMedCrossRefGoogle Scholar
  37. 37.
    Maurer MS, Spevack D, Burkhoff D, et al. Diastolic dysfunction. Can it be diagnosed by Doppler echocardiography? J Am Coll Cardiol 2004;44:1543–1549.PubMedCrossRefGoogle Scholar
  38. 38.
    McCullough PA, Philbin EW, Spertus JA, et al. confirmation of a heart failure epidemic: findings from the resource utilization among congestive heart failure (REACH) study. J Am Coll Cardiol 2002;39:60–69.PubMedCrossRefGoogle Scholar
  39. 39.
    McMurray JJV, Pfeffer MA, Swedberg K, et al. Which inhibitor of the renin-angiotensin system should be used in chronic heart failure and acute myocardial infarction? Circulation 2004;110:3281–3288.PubMedCrossRefGoogle Scholar
  40. 40.
    MERIT-HF: the metoprolol CR/XL randomized intervention trial in congestive heart failure. Effects of controlled release METOPROLOL on total mortality HOSPITALIZATIONS AND well being in patients with heart failure JAMA 2000;283:1295.CrossRefGoogle Scholar
  41. 41.
    Morrison LK, Harrison A, Krishnaswamy P, et al. Utility of a rapid B-natriuretic peptide assay in differentiating congestive heart failure from lung disease in patients presenting with dyspnea. J Am Coll Cardiol 2002;39:202–209.PubMedCrossRefGoogle Scholar
  42. 42.
    Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure: US Carvedilol Heart Failure Study Group. N Engl J Med 1996;334:1349–1355.PubMedCrossRefGoogle Scholar
  43. 43.
    Packer M, Fowler MB, Roecker EB, et al. Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) study. Circulation 2002;106:2194–2187.PubMedCrossRefGoogle Scholar
  44. 44.
    Packer M, Gheorghiade M, Young JB, for the RADIANCE study. Withdrawal of digoxin after treatment of chronic heart failure. N Engl J Med 1993;329:1.PubMedCrossRefGoogle Scholar
  45. 45.
    Packer M, O’Connor CM, Jalal KG, et al. Effect of Amlodipine on morbidity and mortality in severe chronic heart failure. N Engl J Med 1996;335:1107.PubMedCrossRefGoogle Scholar
  46. 46.
    Pina IL. A better survival for women with heart failure? It’s not so simple. J Am Coll Cardiol 2003;42:2135–2138.PubMedCrossRefGoogle Scholar
  47. 47.
    Pitt B. A new HOPE for aldosterone blockade? Circulation 2004;110:1714–1716.PubMedCrossRefGoogle Scholar
  48. 48.
    Pitt B, Remme W, Zannad F, et al., Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003;348:1309–1321.PubMedCrossRefGoogle Scholar
  49. 49.
    Poole-Wilson PA, Cleland JG, Di Lenarda A, et al. Rationale and design of the carvedilol or metoprolol European trial in patients with chronic heart failure: COMET. Eur J Heart Fail 2002;4:321–329.PubMedCrossRefGoogle Scholar
  50. 50.
    RALES: Pitt B, Zannad F, Remme WJ, et al. for the randomized evaluation study investigators; the effect of spironolactone on morbidity and mortality in patients with severe heart failure. New Engl J Med 1999;341:709.PubMedCrossRefGoogle Scholar
  51. 51.
    Redfield MM, Rodeheffer RJ, Jacobsen SJ, et al. plasma brain natriuretic peptide concentration: impact of age and gender. J Am Coll Cardiol 2002;40:976–982.PubMedCrossRefGoogle Scholar
  52. 52.
    Saif S. Rathore, MPH; Jeptha P. Curtis, et al. Association of serum digoxin concentration and outcomes in patients with heart failure JAMA 2003;289:871–878.CrossRefGoogle Scholar
  53. 53.
    Saxon LA, Ellenbogen KA. Resynchronization therapy for the treatment of heart failure. Circulation 2003;108:1044–1048.PubMedCrossRefGoogle Scholar
  54. 54.
    Shea JB, Sweeney MO. Cardiology patient page. Cardiac resynchronization therapy: a patient’s guide. Circulation 2003;108:e64–e66.PubMedCrossRefGoogle Scholar
  55. 55.
    Shekelle PG, Rich MW, Morton SC, et al. efficacy of angiotensin converting enzyme inhibitors and betablockers in the management of the left ventricular systolic dysfunction according to race gender, and diabetic status J Am Coll Cardiol 2003;41:1529–1538.PubMedCrossRefGoogle Scholar
  56. 56.
    The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991;325:293–302.CrossRefGoogle Scholar
  57. 57.
    Uretsky BF, Young JB, Shahidi FE, et al. Randomized study assessing the effect of digoxin withdrawal in patients with mild to moderate chronic congestive heart failure: results of the PROVED trial. J Am Coll Cardiol 1993;22:955.PubMedGoogle Scholar
  58. 58.
    Vasan RS, Levy D. Defining diastolic heart failure: a call for standardized diagnostic criteria. Circulation 2000;101:2118–2121.PubMedGoogle Scholar
  59. 59.
    Waagstein F, Bristow MR, Swedberg K, et al. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Metoprolol in Dilated Cardiomyopathy (MDC) Trial Study Group. Lancet. 1993;342:1441–1446.PubMedCrossRefGoogle Scholar
  60. 60.
    Wiksrrand J, Hjallmarson A, Waagstein F, et al. dose of metoprolol CR/ZL and clinical outcomes in patients with heart failure. J Am Coll Cardiol 2002;40:491.CrossRefGoogle Scholar
  61. 61.
    Wollert KC, Drexler H. Carvedilol prospective randomized cumulative survival (COPERNICUS) trial: carvedilol as the sun and center of the beta-blocker world? Circulation 2002;106:2164–2166.PubMedCrossRefGoogle Scholar
  62. 62.
    The Xamoterol in Severe Heart Failure Study Group. Xamoterol in severe heart failure. Lancet 1990;336:1–6.CrossRefGoogle Scholar
  63. 63.
    Young JB, Abraham WT, Smith AL, et al., Multicenter InSync ICD Randomized Clinical Evaluation (MIRACLE ICD) Trial Investigators. Combined cardiac resynchronization and implantable cardioversion defibrillation in advanced chronic heart failure: the MIRACLE ICD Trial. JAMA 2003;289:2685–2694.PubMedCrossRefGoogle Scholar
  64. 64.
    Zile MR, Brutsaert DL. New concepts in diastolic dysfunction and diastolic heart failure: part I. Circulation 2002;105:1387–1393.PubMedCrossRefGoogle Scholar
  65. 65.
    Zile MR, Brutsaert DL. New concepts in diastolic dysfunction and diastolic heart failure: part II. Circulation 2002;105:1503–1508.PubMedCrossRefGoogle Scholar

Copyright information

© Humana Press Inc., Totowa, NJ 2005

Personalised recommendations